Heck Capital Advisors, LLC Bristol Myers Squibb CO Transaction History

Heck Capital Advisors, LLC

$1.29 Trillion
Q3 2025

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 23, 2025	BUY	$51.92 - $59.94 $172,945 - $199,660	3,331 New	3,331 $188 Million
Q2 2024 May 19, 2025	SELL	$40.25 - $52.99 $2,817 - $3,709	-70 Closed	0 $0
Q4 2023 May 19, 2025	SELL	$48.48 - $57.85 $120,472 - $143,757	-2,485 Reduced 97.26%	70 $3.59 Million
Q3 2023 May 19, 2025	BUY	$57.89 - $64.73 $147,908 - $165,385	2,555 New	2,555 $148 Million
Q2 2023 May 19, 2025	SELL	$63.71 - $70.74 $3,695 - $4,102	-58 Reduced 2.19%	2,587 $165 Million

Q1 2023 May 19, 2025	BUY	$65.71 - $74.53 $6,242 - $7,080	95 Added 3.73%	2,645 $183 Million
Q4 2022 May 19, 2025	BUY	$68.48 - $81.09 $169,830 - $201,103	2,480 Added 3542.86%	2,550 $183 Million
Q3 2022 May 20, 2025	BUY	$0.13 - $76.84 $327 - $193,406	2,517 New	2,517 $179 Million
Q3 2022 May 19, 2025	SELL	$0.13 - $76.84 $312 - $184,800	-2,405 Reduced 97.17%	70 $3.8 Million
Q2 2022 May 19, 2025	SELL	$72.62 - $79.98 $21,786 - $23,994	-300 Reduced 10.81%	2,475 $191 Million
Q1 2022 May 19, 2025	BUY	$61.48 - $73.72 $170,607 - $204,573	2,775 New	2,775 $203 Million
Q4 2021 May 19, 2025	SELL	$53.63 - $62.52 $196,393 - $228,948	-3,662 Reduced 40.4%	5,403 $337 Million
Q3 2021 May 19, 2025	SELL	$59.17 - $69.31 $8,757 - $10,257	-148 Reduced 1.61%	9,065 $536 Million
Q2 2021 May 19, 2025	BUY	$61.91 - $67.42 $6,810 - $7,416	110 Added 1.21%	9,213 $616 Million
Q1 2021 May 19, 2025	SELL	$59.34 - $66.74 $221,160 - $248,739	-3,727 Reduced 29.05%	9,103 $575 Million
Q4 2020 May 19, 2025	SELL	$57.74 - $65.43 $981 - $1,112	-17 Reduced 0.13%	12,830 $796 Million
Q3 2020 May 19, 2025	BUY	$57.43 - $63.64 $737,803 - $817,583	12,847 New	12,847 $775 Million
Q2 2020 May 19, 2025	BUY	$54.82 - $64.09 $279,198 - $326,410	5,093 Added 75.18%	11,867 $698 Million
Q1 2020 May 19, 2025	SELL	$46.4 - $67.43 $8,955 - $13,013	-193 Reduced 2.77%	6,774 $378 Million
Q4 2019 May 19, 2025	BUY	$49.21 - $64.19 $190,737 - $248,800	3,876 Added 125.4%	6,967 $447 Million
Q3 2019 May 19, 2025	BUY	$42.77 - $50.71 $4,576 - $5,425	107 Added 3.59%	3,091 $157 Million
Q2 2019 May 19, 2025	BUY	$44.62 - $49.34 $5,131 - $5,674	115 Added 4.01%	2,984 $135 Million
Q1 2019 May 19, 2025	BUY	$45.12 - $53.8 $129,449 - $154,352	2,869 New	2,869 $137 Million
Q4 2018 May 19, 2025	SELL	$48.76 - $63.23 $128,043 - $166,041	-2,626 Closed	0 $0
Q3 2018 May 19, 2025	SELL	$55.19 - $62.25 $8,830 - $9,960	-160 Reduced 5.74%	2,626 $163 Million
Q2 2018 May 19, 2025	SELL	$50.53 - $62.98 $80,443 - $100,264	-1,592 Reduced 36.36%	2,786 $154 Million
Q1 2018 May 19, 2025	BUY	$59.92 - $68.98 $69,746 - $80,292	1,164 Added 36.22%	4,378 $277 Million
Q4 2017 May 19, 2025	BUY	$59.94 - $65.35 $1,558 - $1,699	26 Added 0.82%	3,214 $197 Million
Q3 2017 May 19, 2025	BUY	$55.23 - $63.74 $87,705 - $101,219	1,588 Added 99.25%	3,188 $203 Million
Q2 2017 May 19, 2025	SELL	N/A	-133 Reduced 7.67%	1,600 $89.2 Million
Q1 2017 May 19, 2025	BUY	N/A	1,733 New	1,733 $94.2 Million
Q4 2016 May 19, 2025	BUY	N/A	1,812	1,812 $106 Million

Others Institutions Holding BMY

# of Institutions

2,688

Shares Held

1.58B

Call Options Held

28M

Put Options Held

28.4M

Vanguard Group Inc Valley Forge, PA

196M
Shares

$9.17 Billion
0.14% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$7.43 Billion
0.15% of portfolio
State Street Corp Boston, MA

96.6M
Shares

$4.52 Billion
0.16% of portfolio
Jpmorgan Chase & CO New York, NY

86.2M
Shares

$4.03 Billion
0.26% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

73M
Shares

$3.42 Billion
0.55% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $99.5B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Heck Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Heck Capital Advisors, LLC with notifications on news.

Account